Stifel Nicolaus Cuts Rating On Endo International plc (ENDP) To "Hold"

Oceane Deschanel
Junho 10, 2017

Zacks' EPS calculations are an average based on a survey of sell-side analysts that follow Endo International plc -. The company is scheduled to issue its next earnings report on Monday, August 14th.

The target price for Endo International plc (ENDP) is $15.88/share according to the consensus of analysts working on the stock, with an expected EPS of $0.72/share for the current quarter. The company reported $1.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.13. This downward move has put the stock in the top loser category moving into the second half of the trading period.Endo International plc (NASDAQ:ENDP) is seeing declines so far in today's trading session. The company's 5 year Earnings per share growth and Capital Spending growth remains at 0 and 20.71. The firm's quarterly revenue was up 7.7% compared to the same quarter past year. Royal Bank of Canada restated a sector perform rating and issued a $15.00 price target on shares of Endo International plc - in a research report on Wednesday, March 15th.

Among 19 analysts covering Endo International plc (NASDAQ:ENDP), 9 have Buy rating, 0 Sell and 10 Hold.

Endo International plc (ENDP) now has P/E (Price to Earnings) ratio of 0 while the company's industry has 13.96 P/E and the sector P/E is 18.75. The stock's 50 day moving average price is $12.25 and its 200 day moving average price is $12.93. RBC Capital Markets maintained Endo International plc - Ordinary Shares (NASDAQ:ENDP) on Wednesday, November 9 with "Outperform" rating. Canaccord Genuity maintained the stock with "Hold" rating in Wednesday, April 12 report. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and six have issued a buy rating to the stock.

Endo International Plc operates as a pharmaceutical company. The company's 50 day moving average price is $12.13 and its 200-day moving average price is $12.96. These ratios are important while doing valuation of the company or the shares of the company. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

"Black Panther" poster unveiled; teaser to debut tonight
If Black Panther can go toe to toe with Captain America, those guys should be a piece of cake...right? Michael B. Back in April, it was revealed that Marvel's Black Panther officially wrapped up production .

The stock diminished about -0.16% in the past 5 years, this negative value indicates that the stock constantly going down in previous years as well.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Finally, Bank of New York Mellon Corp raised its position in shares of Endo International plc - by 38.7% in the first quarter. Gabelli Funds LLC increased its position in Endo International plc - by 14.6% in the fourth quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company's stock valued at $159,000 after buying an additional 4,597 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its position in Endo International plc - by 1.1% in the third quarter. California State Teachers Retirement System now owns 449,599 shares of the company's stock valued at $9,059,000 after buying an additional 4,000 shares during the last quarter. Institutional investors own 95.50% of the company's stock. Credit Agricole S A invested 0.04% in Endo International plc - Ordinary Shares (NASDAQ:ENDP). The company had a trading volume of 4,559,836 shares. It is positive, as 36 investors sold Endo International plc - Ordinary Shares shares while 86 reduced holdings.

Stock is now moving with a negative distance from the 200 day simple moving average of approximately -9.17%, and has a poor year to date (YTD) performance of -16.33% which means the stock is constantly subtracting to its value from the previous fiscal year end price. The stock's market cap is $2.89 billion.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX.

Outros relatórios LazerEsportes

Discuta este artigo